Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

Summary

Albert Bourla discusses Pfizer's strong Q1 results, emphasizing commercial execution and a robust pipeline from acquisitions like Seagen and Biohaven. He highlights progress in oncology, obesity, and immunology, and addresses FDA/CDC dynamics, China licensing, and European pricing. Bourla is optimistic about Pfizer's future as a leading growth company.

• Pfizer beat Q1 estimates driven by commercial execution and 22% growth in new/acquired products.
• Bourla highlights $80B in acquisitions (Seagen, Biohaven, obesity platform) to offset patent losses.
• Seagen shows 20% growth and significant readouts in bladder cancer; Biohaven migraine drug grows 41%.
• Obesity peptide platform to start ten phase 3 trials this year.
• Bourla is optimistic about FDA modernization under Makary and new CDC director Erica Schwartz.
• Pfizer is licensing early-stage Chinese science for oncology and obesity, planning U.S. launch.
• Bourla warns European countries must pay fair share for innovation or risk losing access to new drugs.
• Pfizer aims to become a leading industry growth company through AI-driven transformation.